conv.

All stories
HealthQuiet · 29h

Sionna's cystic fibrosis pill fails mid-stage trial, stock collapses 92%

Sionna Therapeutics' experimental CF drug showed no added benefit when combined with Vertex's Trikafta blockbuster.

4 items0 engagement0 comments PressGoogle News

Conversation activity · last 38 hours peak 1/hr

Peak 1 item in one hour at Aug 10, 7 AM; 4 items over 38 hours Aug 10, 7 AM — 1 item · Press 1Aug 10, 8 AM — 1 item · Press 1Aug 10, 9 AM — 1 item · Google News 1Aug 10, 10 AM — no itemsAug 10, 11 AM — no itemsAug 10, 12 PM — no itemsAug 10, 1 PM — no itemsAug 10, 2 PM — no itemsAug 10, 3 PM — 1 item · Google News 1Aug 10, 4 PM — no itemsAug 10, 5 PM — no itemsAug 10, 6 PM — no itemsAug 10, 7 PM — no itemsAug 10, 8 PM — no itemsAug 10, 9 PM — no itemsAug 10, 10 PM — no itemsAug 10, 11 PM — no itemsAug 11, 12 AM — no itemsAug 11, 1 AM — no itemsAug 11, 2 AM — no itemsAug 11, 3 AM — no itemsAug 11, 4 AM — no itemsAug 11, 5 AM — no itemsAug 11, 6 AM — no itemsAug 11, 7 AM — no itemsAug 11, 8 AM — no itemsAug 11, 9 AM — no itemsAug 11, 10 AM — no itemsAug 11, 11 AM — no itemsAug 11, 12 PM — no itemsAug 11, 1 PM — no itemsAug 11, 2 PM — no itemsAug 11, 3 PM — no itemsAug 11, 4 PM — no itemsAug 11, 5 PM — no itemsAug 11, 6 PM — no itemsAug 11, 7 PM — no itemsAug 11, 8 PM — no items 1 item · 7 AM
8 AM4 PMAug 118 AMnow · 9:06 PM

Summary, timeline and people extracted by Claude from 4 items across 2 sources · 21h ago. Quotes are verbatim.

Sionna Therapeutics announced that its experimental cystic fibrosis pill failed to meet key endpoints in a mid-stage trial when combined with Vertex's market-leading CF drug Trikafta. The clinical failure triggered a dramatic 92% stock collapse. The result removes a competitive threat to Vertex's dominant position in the CF market.

  • Sionna's experimental CF drug failed to show added benefit when combined with Vertex's Trikafta in mid-stage trial
  • Stock collapsed 92-100% on announcement of trial failure
  • Result eliminates competitive threat to Vertex's dominant cystic fibrosis market position

How it unfolded

  1. Report Stock decline approaches total collapse

    Multiple financial and biotech news outlets reported Sionna's stock plunging nearly 100% in response to the failed cystic fibrosis trial.

  2. Reaction Markets react sharply to trial miss

    Sionna's stock price collapsed approximately 92% following the announcement that the drug missed its key trial endpoint.

  3. Event Sionna CF trial failure announced

    Sionna Therapeutics disclosed that its experimental cystic fibrosis pill failed to provide added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta in a mid-stage trial.

What people are saying verbatim

“A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.”

STAT News, Healthcare news outlet · STAT News ↗ · Aug 9